DE69825906D1 - Verwendung von angiostatische steroide in photodynamischer therapie - Google Patents

Verwendung von angiostatische steroide in photodynamischer therapie

Info

Publication number
DE69825906D1
DE69825906D1 DE69825906T DE69825906T DE69825906D1 DE 69825906 D1 DE69825906 D1 DE 69825906D1 DE 69825906 T DE69825906 T DE 69825906T DE 69825906 T DE69825906 T DE 69825906T DE 69825906 D1 DE69825906 D1 DE 69825906D1
Authority
DE
Germany
Prior art keywords
photodynamic therapy
angiostatic steroids
angiostatic
steroids
steriod
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69825906T
Other languages
English (en)
Other versions
DE69825906T2 (de
Inventor
Abbot F Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Research LLC
Original Assignee
Alcon Manufacturing Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Manufacturing Ltd filed Critical Alcon Manufacturing Ltd
Publication of DE69825906D1 publication Critical patent/DE69825906D1/de
Application granted granted Critical
Publication of DE69825906T2 publication Critical patent/DE69825906T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J11/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J3/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0027Azides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J51/00Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
DE69825906T 1997-07-16 1998-06-18 Verwendung von angiostatische steroide in photodynamischer therapie Expired - Fee Related DE69825906T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US895184 1997-07-16
US08/895,184 US5770592A (en) 1991-11-22 1997-07-16 Prevention and treatment of ocular neovascularization using angiostatic steroids
PCT/US1998/012711 WO1999003503A1 (en) 1997-07-16 1998-06-18 The use of angiostatic steroids in photodynamic therapy

Publications (2)

Publication Number Publication Date
DE69825906D1 true DE69825906D1 (de) 2004-09-30
DE69825906T2 DE69825906T2 (de) 2005-09-01

Family

ID=25404127

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69825906T Expired - Fee Related DE69825906T2 (de) 1997-07-16 1998-06-18 Verwendung von angiostatische steroide in photodynamischer therapie

Country Status (13)

Country Link
US (2) US5770592A (de)
EP (1) EP1003553B1 (de)
JP (1) JP2001510170A (de)
AT (1) ATE274356T1 (de)
AU (1) AU734195B2 (de)
BR (1) BR9811012A (de)
CA (1) CA2296558A1 (de)
DE (1) DE69825906T2 (de)
DK (1) DK1003553T3 (de)
ES (1) ES2224412T3 (de)
HK (1) HK1028952A1 (de)
PT (1) PT1003553E (de)
WO (1) WO1999003503A1 (de)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1154691A4 (de) * 1999-01-05 2004-07-07 Massachusetts Eye & Ear Infirm Gezielte transsklerale gesteuerte wirkstoffabgabe an die retina und choroidae
WO2000041725A2 (en) * 1999-01-15 2000-07-20 Light Sciences Corporation Therapeutic compositions for metabolic bone disorders or bone metastases
CA2356532A1 (en) 1999-01-15 2000-07-20 Light Sciences Corporation Noninvasive vascular therapy
US6602274B1 (en) 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
US7943162B2 (en) * 1999-10-21 2011-05-17 Alcon, Inc. Drug delivery device
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
EP1221918B1 (de) 1999-10-21 2005-03-16 Alcon Inc. Medikamentenversorgung der sub-tenon
ATE283013T1 (de) 1999-10-21 2004-12-15 Alcon Inc Medikamentenzuführvorrichtung
US7678836B2 (en) * 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
CA2398901C (en) * 2000-02-10 2010-11-16 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
AU5040101A (en) * 2000-03-24 2001-10-15 Novartis Ag Improved treatment of neovascularization
EP1570859A3 (de) * 2000-03-24 2008-04-02 Novartis AG Verbesserte Behandlung von Neovaskularisation
CA2446143C (en) * 2000-05-19 2010-01-19 Michael S. Berlin Delivery system and method of use for the eye
US8679089B2 (en) 2001-05-21 2014-03-25 Michael S. Berlin Glaucoma surgery methods and systems
US9603741B2 (en) 2000-05-19 2017-03-28 Michael S. Berlin Delivery system and method of use for the eye
US7563255B2 (en) 2001-05-03 2009-07-21 Massachusetts Eye And Ear Infirmary Implantable drug delivery device and use thereof
JP4249611B2 (ja) * 2001-07-23 2009-04-02 アルコン,インコーポレイティド 眼薬剤送致装置
PL204644B1 (pl) 2001-07-23 2010-01-29 Alcon Okulistyczne urządzenie do podawania leków
US7402577B2 (en) * 2001-10-03 2008-07-22 Merck & Co., Inc. Androstane 17-beta-carboxamides as androgen receptor modulators
CN1582156A (zh) * 2001-11-09 2005-02-16 眼科技术药物公司 眼新血管疾病的治疗方法
US6723750B2 (en) 2002-03-15 2004-04-20 Allergan, Inc. Photodynamic therapy for pre-melanomas
WO2003092665A2 (en) * 2002-05-02 2003-11-13 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
WO2004011460A2 (en) 2002-07-24 2004-02-05 Qlt, Inc. Pyrazolylbenzothiazole derivatives and their use as therapeutic agents
WO2004011544A1 (en) * 2002-07-29 2004-02-05 Ast Products, Inc. Ophtalmic compositions
US6828356B2 (en) * 2002-07-29 2004-12-07 Ast Products, Inc. Preparation of ophthalmic compositions
US6806364B2 (en) * 2002-07-29 2004-10-19 Ast Products, Inc. Ophthalmic compositions
PL375024A1 (en) * 2002-08-05 2005-11-14 Alcon, Inc. Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration
DE10238310A1 (de) * 2002-08-21 2004-03-04 Erich Jaeger Gmbh Elektrodenanordnung
CA2500877A1 (en) * 2002-10-03 2004-04-15 Light Sciences Corporation Excitation of photoreactive compounds in eye tissue
WO2004073551A2 (en) * 2003-02-18 2004-09-02 Massachusetts Eye And Ear Infirmary Transscleral drug delivery device and related methods
WO2004073607A2 (en) * 2003-02-20 2004-09-02 Alcon, Inc. Use of steroids to treat ocular disorders
EP1594511A2 (de) * 2003-02-20 2005-11-16 Alcon, Inc. Glucocorticoid-formulierungen zur behandlung von pathologischer angiogenese im auge
KR20060019579A (ko) * 2003-06-13 2006-03-03 알콘, 인코퍼레이티드 병적 눈 혈관형성을 치료하기 위한 비-스테로이드성항-염증제 제제
EP1635842A4 (de) * 2003-06-20 2007-04-04 Alcon Inc Behandlung von amd mit einer kombination von inhaltsstoffen
MXPA05011517A (es) * 2003-07-10 2005-12-12 Alcon Inc Dispositivo para el suministro de medicamentos oftalmicos.
US7585517B2 (en) * 2003-09-18 2009-09-08 Macusight, Inc. Transscleral delivery
CN1852700A (zh) * 2003-09-23 2006-10-25 爱尔康公司 曲安奈德和醋酸阿奈可他注射用制剂
WO2005072744A1 (ja) * 2004-02-02 2005-08-11 Yuichi Kaji 硝子体の可視化剤
CN1980929A (zh) * 2004-02-24 2007-06-13 比奥阿克松医疗技术股份有限公司 4-取代哌啶衍生物
US20050239760A1 (en) * 2004-04-23 2005-10-27 Alcon, Inc. Angiostatic agents and methods and compositions for controlling ocular hypertension
JP2008514645A (ja) 2004-09-24 2008-05-08 アールエフイー ファーマ エルエルシー 眼疾患およびその他の疾患の局所的処置のためのcaiに基づくシステムおよび方法
US20160106717A1 (en) 2004-09-24 2016-04-21 Gen Pharma Holdings LLC Cai-based systems and methods for the localized treatment of uveitis
US20060107555A1 (en) * 2004-11-09 2006-05-25 Curtis Marc D Universal snow plow adapter
WO2006086750A1 (en) * 2005-02-09 2006-08-17 Macusight, Inc. Liquid formulations for treatment of diseases or conditions
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
EP2292672B1 (de) 2005-05-25 2018-05-09 CIS Pharma AG Bioverträgliche Polymere und Copolymere mit Aminosäuren in der Seitenkette
EP2468318A1 (de) * 2005-07-12 2012-06-27 DMI Biosciences, Inc. Verfahren und Produkte zur Behandlung von Erkrankungen
WO2007014327A2 (en) 2005-07-27 2007-02-01 University Of Florida Research Foundation, Inc. Small compounds that correct protein misfolding and uses thereof
US7758778B2 (en) * 2005-09-07 2010-07-20 Southwest Research Institute Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US9693967B2 (en) * 2005-09-07 2017-07-04 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates
US7261529B2 (en) * 2005-09-07 2007-08-28 Southwest Research Institute Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents
ES2681656T3 (es) 2005-09-07 2018-09-14 Amgen Fremont Inc. Anticuerpos monoclonales humanos para quinasa-1 de tipo receptor de activina (ALK-1)
AU2006304553A1 (en) * 2005-10-14 2007-04-26 Alcon, Inc. Method for treating primary and secondary forms of glaucoma
US20080125406A1 (en) * 2005-10-14 2008-05-29 Robin Alan L Method for Treating Primary and Secondary Forms of Glaucoma
WO2007047626A1 (en) * 2005-10-14 2007-04-26 Alcon, Inc. Combination treatment with anecortave acetate and bevacizumab or ranibizumab for pathologic ocular angiogenesis
CA2628570A1 (en) 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
EP2329821B1 (de) 2005-11-29 2012-08-22 GlaxoSmithKline LLC Behandlung von neovaskulären Augenerkrankungen, wie z.B. Maculadegeneration, angioiden Streifen, Uveitis und Makulaödemen
CA2635797C (en) 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
KR101520408B1 (ko) 2006-03-23 2015-05-14 산텐 세이야꾸 가부시키가이샤 혈관 투과성-관련 질환 또는 상태를 위한 제형 및 방법
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
US20170360609A9 (en) 2007-09-24 2017-12-21 Ivantis, Inc. Methods and devices for increasing aqueous humor outflow
US20090181933A1 (en) * 2008-01-11 2009-07-16 Bingaman David P Use of steroids to treat persons suffering from ocular disorders
JP2011513002A (ja) 2008-03-05 2011-04-28 イバンティス インコーポレイテッド 緑内障を治療する方法及び器具
EP2278978B1 (de) 2008-05-28 2015-09-02 ReveraGen BioPharma, Inc. Nichthormonale steroide modulatoren von nf-kb zur krankheitsbehandlung
US8372036B2 (en) 2009-05-06 2013-02-12 Alcon Research, Ltd. Multi-layer heat assembly for a drug delivery device
IN2012DN00352A (de) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
ES2554688T3 (es) 2009-06-22 2015-12-22 Ampio Pharmaceuticals, Inc. Procedimiento de tratamiento de enfermedades
EP2445350A4 (de) * 2009-06-22 2012-12-26 Dmi Acquisition Corp Verfahren und produkte zur behandlung von erkrankungen
AU2010271274B2 (en) 2009-07-09 2015-05-21 Alcon Inc. Single operator device for delivering an ocular implant
AU2010271218B2 (en) 2009-07-09 2017-02-02 Alcon Inc. Ocular implants and methods for delivering ocular implants into the eye
WO2011039648A1 (en) 2009-09-30 2011-04-07 Glaxo Wellcome Manufacturing Pte Ltd. Methods of administration and treatment
US8177747B2 (en) 2009-12-22 2012-05-15 Alcon Research, Ltd. Method and apparatus for drug delivery
US9198921B2 (en) 2010-04-05 2015-12-01 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-κB for treatment of disease
US20120283557A1 (en) 2011-05-05 2012-11-08 Berlin Michael S Methods and Apparatuses for the Treatment of Glaucoma using visible and infrared ultrashort laser pulses
US9133082B2 (en) 2011-06-14 2015-09-15 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US8657776B2 (en) 2011-06-14 2014-02-25 Ivantis, Inc. Ocular implants for delivery into the eye
EP2768307B1 (de) 2011-10-19 2020-03-18 Bikam Pharmaceuticals, Inc. Opsinbindende liganden, zusammensetzungen damit und anwendungsverfahren dafür
AU2012346214B2 (en) 2011-11-30 2017-09-14 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
WO2013081642A1 (en) 2011-12-01 2013-06-06 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US8663150B2 (en) 2011-12-19 2014-03-04 Ivantis, Inc. Delivering ocular implants into the eye
US9358156B2 (en) 2012-04-18 2016-06-07 Invantis, Inc. Ocular implants for delivery into an anterior chamber of the eye
US10617558B2 (en) 2012-11-28 2020-04-14 Ivantis, Inc. Apparatus for delivering ocular implants into an anterior chamber of the eye
EP2934546A4 (de) 2012-12-19 2016-06-22 Ampio Pharmaceuticals Inc Verfahren zur krankheitsbehandlung
WO2016011056A1 (en) 2014-07-14 2016-01-21 Ivantis, Inc. Ocular implant delivery system and method
US10857157B2 (en) 2015-01-26 2020-12-08 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US10149856B2 (en) 2015-01-26 2018-12-11 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US10106525B2 (en) 2015-01-26 2018-10-23 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
WO2017004205A1 (en) 2015-06-29 2017-01-05 Reveragen Biopharma, Inc. NON-HORMONAL STEROID MODULATORS OF NF-κB FOR TREATMENT OF DISEASE
EP4265231A3 (de) 2015-08-14 2023-12-20 Alcon Inc. Augenimplantat mit drucksensor
US11198680B2 (en) 2016-12-21 2021-12-14 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US10537567B2 (en) 2017-07-11 2020-01-21 BioAxone BioSciences, Inc. Kinase inhibitors for treatment of disease
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions
JP2024503989A (ja) 2021-01-11 2024-01-30 アルコン インコーポレイティド 粘弾性体送達のためのシステム及び方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975537A (en) * 1985-10-23 1990-12-04 The Upjohn Company Δ9(11) -angiostatic steroids
US4771042A (en) * 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
US4876250A (en) * 1988-10-31 1989-10-24 Alcon Laboratories, Inc. Methods for controlling ocular hypertension with angiostatic steroids
US5371078A (en) * 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
ATE190623T1 (de) * 1990-06-11 2000-04-15 Alcon Lab Inc Verwendung von steroiden zur inhibierung von angiogenesis
CA2185644C (en) * 1994-03-14 2011-04-12 Joan W. Miller Use of green porphyrins in ocular diagnosis and therapy

Also Published As

Publication number Publication date
EP1003553B1 (de) 2004-08-25
ES2224412T3 (es) 2005-03-01
PT1003553E (pt) 2004-10-29
US6297228B1 (en) 2001-10-02
US5770592A (en) 1998-06-23
WO1999003503A1 (en) 1999-01-28
ATE274356T1 (de) 2004-09-15
HK1028952A1 (en) 2001-03-16
EP1003553A1 (de) 2000-05-31
CA2296558A1 (en) 1999-01-28
BR9811012A (pt) 2000-10-17
AU734195B2 (en) 2001-06-07
DE69825906T2 (de) 2005-09-01
DK1003553T3 (da) 2004-09-20
JP2001510170A (ja) 2001-07-31
AU8151598A (en) 1999-02-10

Similar Documents

Publication Publication Date Title
DE69825906D1 (de) Verwendung von angiostatische steroide in photodynamischer therapie
AU2207000A (en) Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
ATE324119T1 (de) Verwendung von saccharid-konjugaten
DE69434491D1 (de) Hautpflaster enthaltend testosteron und gegebenenfalls estrogen
ATE424211T1 (de) Therapeutische verwendung von sapogeninen
DE60040753D1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
DE60216300D1 (de) Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
ATE247709T1 (de) 3'utr des menschliches prohibitin-gens
ATE442861T1 (de) Gegen antikörper gerichtete photodynamische therapie
TR199901003T2 (xx) Ast�m tedavisi i�in loratadin ve bir dekonjestan i�eren bile�im.
DE69705421D1 (de) 15-fluoro-prostaglandine als augendrucksenkende mittel
DE69729004D1 (de) Photodynamische therapie zur behandlung von osteosrthritis
ATE306270T1 (de) Verwendung von fulvestrant in der behandlung von resistentem brustkrebs
DE69710333T2 (de) Cyclopentan(en)säure-2-alkenyl-derivate als therapeutika in der behandlung der okulären hypertonie
DE69912304D1 (de) Verwendung von staurosporine derivaten zur behandlung von okularen neovaskularen erkrankungen
TW200507858A (en) Formulations of glucocorticoids to treat pathologic ocular angiogenesis
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
DE69821227D1 (de) Verwendung von papovavirus kapsid-proteinen zur verabreichung therapeutischen agentien in nervzellen
DE60319719D1 (de) Verfahren zur voraussage der erhöhung von cholesterin während einer immunosuppresiven therapie
DK0900085T3 (da) Behandling af overdreven aggression med olanzapin
ATE271878T1 (de) Verwendung von protein h als zytostattischer wirkstoff
PT1169026E (pt) Utilizacao de activadores de ap-1 no tratamento do glaucoma e da hipertensao ocular
UA43728A (uk) Спосіб лікування раку передміхурової залози

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee